< Back to search
Filter
1
FeaturedActive & Responsive

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

for
Solid Tumor
Location: Boston MA, New Haven CT, The Bronx NY, Montreal,
Sponsor: Genentech, Inc.

Sex: All

Age: 18+

Code: NCT06619587

Phase 1, Recruiting
Featured

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400

for
Hepatocellular Carcinoma, Pancreatic Ductal Adenocarcinoma,
Location: Providence RI, New York NY, Fairfax VA, Durham NC,
Sponsor: AbbVie

Sex: All

Age: 18+

Code: NCT06084481

Phase 1, Recruiting
Featured

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)

for
Neoplasms
Location: New Haven CT, Toronto, Sarasota FL, Houston TX,
Sponsor: Hoffmann-La Roche

Sex: All

Age: 18+

Code: NCT06884618

Phase 1, Recruiting
Active & Responsive

A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors

for
Solid Tumor
Location: New York NY, Philadelphia PA, Washington D.C. DC,
Sponsor: Biohaven Therapeutics Ltd.

Sex: All

Age: 18+

Code: NCT06384807

Phase 1, Phase 2, Recruiting
Active & Responsive

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

for
Cancer, PDAC - Pancreatic Ductal Adenocarcinoma,
Location: Boston MA, New York NY, Fairfax VA, Durham NC,
Sponsor: Alterome Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT06835569

Phase 1, Recruiting

Interested in new solid tumors trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

for
Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung,
Location: New York NY, Jacksonville FL, Tampa FL, Columbus OH,
Sponsor: A2 Biotherapeutics Inc.

Sex: All

Age: 18+

Code: NCT06682793

Phase 1, Phase 2, Recruiting
Active & Responsive

First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer

for
PIK3CA Mutation, Solid Tumor, Adult,
Location: Boston MA, New Haven CT, New York NY, New Brunswick NJ,
Sponsor: Relay Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05216432

Phase 1, Recruiting
Active & ResponsiveNew

A Study of DS3610a in Participants With Advanced Solid Tumor

for
Solid Tumors, Metastatic Solid Tumors
Location: Milwaukee WI
Sponsor: Daiichi Sankyo

Sex: All

Age: 18+

Code: NCT07159126

Phase 1, Recruiting
Active & Responsive

Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors

for
Advanced Solid Tumor
Location: East Providence RI, Charleston SC, Huntersville NC,
Sponsor: BioNTech SE

Sex: All

Age: 18+

Code: NCT06750185

Phase 1, Phase 2, Recruiting
Active & Responsive

A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors With or Without Brain Metastases

for
Solid Tumor Malignancies, Brain Metastases From Solid Tumors
Location: Fairfax VA, Charleston SC, Detroit MI, Houston TX,
Sponsor: A2A Pharmaceuticals Inc.

Sex: All

Age: 18+

Code: NCT06136884

Phase 1, Recruiting
Active & Responsive

FOG-001 in Locally Advanced or Metastatic Solid Tumors

for
Cancer, Colorectal Cancer, Solid Tumor,
Location: Boston MA, New Haven CT, New York NY, Philadelphia PA,
Sponsor: Parabilis Medicines, Inc.

Sex: All

Age: 18+

Code: NCT05919264

Phase 1, Phase 2, Recruiting
Active & Responsive

A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

for
Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer,
Location: New Haven CT, Lake Success NY, New York NY, Fairfax VA,
Sponsor: Cogent Biosciences, Inc.

Sex: All

Age: 18+

Code: NCT07361562

Phase 1, Recruiting
Active & Responsive

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

for
Solid Tumor, Adult, Colorectal Cancer,
Location: New York NY, Jacksonville FL, Tampa FL, Columbus OH,
Sponsor: A2 Biotherapeutics Inc.

Sex: All

Age: 18+

Code: NCT04981119

Recruiting
Active & Responsive

Safety and Preliminary Efficacy of SA53-OS in Patients With Locally Advanced or Metastatic Solid Tumors

for
Solid Tumor
Location: Canton OH, Cleveland OH
Sponsor: Lamassu Bio Inc

Sex: All

Age: 18+

Code: NCT06578624

Phase 1, Phase 2, Recruiting
Active & Responsive

PAS-004 in Patients With Advanced Solid Tumors

for
RAS Mutation, NF1 Mutation, RAF Mutation, Advanced Solid Tumors
Location: Fairfax VA, Irving TX, San Antonio TX
Sponsor: Pasithea Therapeutics Corp.

Sex: All

Age: 18+

Code: NCT06299839

Phase 1, Recruiting
Active & Responsive

Phase 1 Dose Escalation and Expansion Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Patients With Advanced Solid Tumors (TROPIKANA)

for
Solid Tumors
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06066424

Phase 1, Recruiting
Active & Responsive

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

for
Solid Tumor, Adult, Colorectal Cancer, NSCLC,
Location: New York NY, Jacksonville FL, Tampa FL, Columbus OH,
Sponsor: A2 Biotherapeutics Inc.

Sex: All

Age: 18+

Code: NCT06051695

Phase 1, Phase 2, Recruiting
Active & Responsive

NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors

for
Solid Tumor, KRAS Mutation-Related Tumors
Location: Washington D.C. DC
Sponsor: Georgetown University

Sex: All

Age: 18+

Code: NCT05661201

Phase 1, Recruiting
Active & Responsive

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

for
Advanced Solid Tumors, Genital Neoplasm, Female,
Location: Boston MA, Bethesda MD, Toronto, Celebration FL,
Sponsor: Marengo Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05592626

Phase 1, Phase 2, Recruiting
Active & Responsive

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

for
Advanced Solid Tumor
Location: Pittsburgh PA, Houston TX, Beverly Hills CA
Sponsor: Strand Therapeutics Inc.

Sex: All

Age: 18+

Code: NCT06249048

Phase 1, Phase 2, Recruiting